Gyre Therapeutics (GYRE) Profit After Tax (2010 - 2026)

Gyre Therapeutics (GYRE) has reported Profit After Tax for 17 consecutive years, with -$9.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Profit After Tax fell 364.01% year-over-year to -$9.9 million; the TTM figure through Mar 2026 stood at -$3.7 million (down 131.34% YoY), while the FY2025 annual figure was $9.9 million, down 44.8% from the prior year.
• Profit After Tax eased to -$9.9 million in Q1 2026 per GYRE's latest filing, from -$1.3 million in the prior quarter.
• Across five years, Profit After Tax topped out at $51.6 million in Q2 2022 and bottomed at -$101.0 million in Q4 2023.
• Historically, Profit After Tax has averaged -$3.7 million across 5 years, with a median of $2.9 million in 2024.
• Annual changes were most pronounced in 2022 — Profit After Tax jumped 359.09% — and 2026, when it plunged 364.01%.
• Gyre Therapeutics' Profit After Tax stood at -$27.9 million in 2022, then tumbled by 261.95% to -$101.0 million in 2023, then jumped by 100.56% to $569000.0 in 2024, then sank by 331.99% to -$1.3 million in 2025, then slumped by 646.82% to -$9.9 million in 2026.
• Business Quant data shows GYRE's Profit After Tax at -$9.9 million in Q1 2026, -$1.3 million in Q4 2025, and $5.9 million in Q3 2025.